Frontpage Hero

Because we care, we need to act

Sobi Scientific Innovation Awards

Sobi Scientific Innovation Awards

Entries are now being accepted for the inaugural Sobi Scientific Innovation Awards. This year’s awards, which recognise innovation and scientific excellence in haemophilia research, have a focus on the future of haemophilia care and the ability to help liberate life for people with haemophilia.
Sobi 2018 Annual and Sustainability Report

Sobi 2018 Annual and Sustainability Report

"2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see this as an important stepping stone. In the Annual and Sustainability Report, we outline how the strong growth we delivered throughout 2018 is fuelling our vision of becoming global leaders in providing innovative treatments that transform life for people with rare diseases".

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M. A PRV entitles the holder to FDA priority review...

08/22/2019 - 08:00

Following approvals from relevant competition authorities Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has completed the acquisition of the newly established company owning emapalumab and related assets, as announced on 12 June 2019. The acquisition means that...

07/18/2019 - 12:10

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38 per cent revenue growth in the quarter compared with Q2 2018 (32 per cent at constant exchange rates (CER)). Organic growth...

07/17/2019 - 08:00

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi™) on 9 May 2019, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed...

07/16/2019 - 18:30
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden